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Background: Familial hypercholesterolemia (FH) is an autosomal-dominant disease leading to markedly elevated
low-density lipoprotein (LDL) cholesterol levels and increased risk for premature myocardial infarction (MI). Mutation
carriers display variable LDL cholesterol levels, which may obscure the diagnosis. We examined by whole-exome
sequencing a family in which multiple myocardial infarctions occurred at a young age with unclear etiology.
Methods: Whole-exome sequencing of three affected family members, validation of the identified variant with
Sanger-sequencing, and subsequent co-segregation analysis in the family.
Results: The index patient (LDL cholesterol 188 mg/dL) was referred for molecular-genetic investigations. He had
coronary artery bypass graft (CABG) at the age of 59 years; 12 out of 15 1st, 2nd and 3rd degree relatives were
affected with coronary artery disease (CAD) and/or premature myocardial infarction (MI). We sequenced the
whole-exome of the patient and two cousins with premature MI. After filtering, we were left with a potentially disease
causing variant in the LDL receptor (LDLR) gene, which we validated by Sanger-sequencing (nucleotide substitution in
the acceptor splice-site of exon 10, c.1359-1G > A). Sequencing of all family members available for genetic analysis
revealed co-segregation of the variant with CAD (LOD 3.0) and increased LDLC (>190 mg/dL), following correction for
statin treatment (LOD 4.3). Interestingly, mutation carriers presented with highly variable corrected (183–354 mg/dL)
and on-treatment LDL levels (116–274 mg/dL) such that the diagnosis of FH in this family was made only after the
molecular-genetic analysis.
Conclusion: Even in families with unusual clustering of CAD FH remains to be underdiagnosed, which underscores the
need for implementation of systematic screening programs. Whole-exome sequencing may facilitate identification of
disease-causing variants in families with unclear etiology of MI and enable preventive treatment of mutation carriers in
a more timely fashion.
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Familial hypercholesterolemia (FH) may explain as much
as 20 percent of familial cases with premature coronary
artery disease (CAD) [1,2]. Despite well-established cri-
teria for clinical diagnosis and the proven benefits of med-
ical treatment FH remains to be largely under-diagnosed
and untreated [3]. In most European populations between
5-15% of cases are diagnosed [4,5]. It has been considered
that many FH cases are simply overlooked in the large
number of CAD patients, a disease usually caused multi-
factorially by the interplay of common risk factors and
common risk alleles [4,6]. Moreover, with significant im-
pact, the fact that nowadays most families are small may
mask the inherited nature of the disease [7,8].
In cases with suspected FH, family-based cascade screen-
ing by either clinical or molecular-genetic instruments is
guideline recommended to unravel the autosomal-dominant
mode of inheritance and to facilitate medical treatment at
a young age (European Society of Cardiology [9], British
National Institute for Clinical Excellence (NICE) [10], US
Centres for Disease Control and Prevention [11]).
Yet, such testing either using lipid panels paired with
clinical diagnostic criteria or molecular-genetic DNA se-
quencing of the currently known disease-causing genes
is vastly under-used [4,12,13]. Exceptions are found in
the Netherlands and Norway, where national screening
programs for mutations in the disease-causing genes
LDLR, APOB and PCSK9 have been initiated [4,14,15].
Here, we report on an extended MI-family, which
remained without diagnosis until whole-exome sequencingA
B
Figure 1 Pedigree of the analyzed family and confirmation of mutatio
members selected for whole-exome sequencing are III.3, III.18, and IV.7. Ele
are shown as G/A and non-carriers as G/G. B) Confirmation of the nucleoti
Sanger sequencing. Shown is the sequence of the index patient IV.7. The bwas performed. The index patient was referred to us
because of premature MI (CABG at the age of 59) and
positive family history for CAD (rather than for ele-
vated LDL-cholesterol levels, LDL-C). His LDL-C was
188 mg/dL, which initially detracted from a clinical
suspicion of FH. The family with 15 CAD cases (plus
two that are related by marriage) and several untreated
mutation carriers illustrates the need for a more system-
atic employment of molecular FH testing to increase the
awareness and timely initiation of medical treatment.Methods
MI family
The index patient had suffered from CABG at the age of
59 years. Figure 1A depicts the pedigree of the MI family
used for whole-exome sequencing. Clinical and angio-
graphic characteristics of the family members available
for analysis are described in detail in Table 1. All sub-
jects analyzed in this study gave written informed con-
sent before participating. The local Ethical Committee
(University Regensburg, Germany) approved the study.Exome sequencing
Whole-exome sequencing was performed as 54 bp paired-
end runs on a Genome Analyzer IIx system (Illumina)
after in-solution enrichment of exonic sequences (SureSelect
Human All Exon 50 Mb kit, Agilent). Reads are mapped
to the reference genome, duplicate fragments are marked
using Picard and GATK is then used to recalibrate basen by Sanger sequencing. A) The index patient is IV.7. The family
vated LDL-C levels are shown as half filled symbols. Mutation carriers
de substitution in the acceptor splice-site of exon 10, c.1359-1G > A by
lack arrow points to the heterozygote position.





















6652501 III.2 2 28.5 58 252 Atorvastatin 20 1 1 2 1
6652502 III.3 1 26.5 55 214 Atorvastatin 60 1 1 2 2
6652505 III.16 2 22.8 186 2 1 2 2
6652506 III.18 2 25.0 55 233 Atorvastatin 80 1 2 2 1
6652509 IV.6 2 26.4 184 2 2 2 1
6652511 III.6 1 25.9 44 67 189 Atorvastatin 10 1 1 2 1
6652512 III.20 1 30.5 136 Cerivastatin 0.3 1 1 2 2
6652513 IV.3 1 24.2 96 2 2 2 2
6652515 IV.5 2 23.4 171 2 2 2 1
6652516 IV.7 1 25.2 59 188 Atorvastatin 40 1 2 2 2
6652518 III.13 2 27.3 156 2 2 2 1
6652520 IV.9 1 22.5 142 Simvastatin 10 1 2 2
6652522 IV.13 1 29.4 166 2 2 2 1
6652523 IV.14 2 24.2 168 2 2 2 2
6652524 IV.15 2 23.5 130 2 2 2
6652525 IV.16 1 22.7 145 2 2 2 2
6652527 IV.20 2 23.4 143 2 2 1
6652531 IV.10 2 20.9 116 Atorvastatin 60 1 2 2 2
6652533 IV.12 2 21.3 2 2 2
6652534 III.19 1 23.1 115 2 1 2 2
6652535 IV.17 1 23.2 184 2 2 2 2
6652536 IV.18 1 22.8 274 Atorvastatin 20 1 2 2 2
$:1 =male, 2 = female; #: 1 = yes, 2 = no; 1Blood pressure >140/90 mm Hg; 2LDL cholesterol > 190 mg/dL or statin therapy; 3History of diabetes mellitus; 4History of
smoking. Index patient IV.7 in bold.
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(GRCh37) as reference.
Mutation validation
We annotated the single nucleotide variants (SNVs) with
Annovar [16] using the UCSC database, Exome sequen-
cing project and 1000 Genomes. Protein altering effect
was predicted using SnpEFF [17] and avsift (Annovar).
Mutation validation was performed by PCR and Sanger-
sequencing of candidate gene region identified by whole-
exome sequencing. After confirmation of the variant
(Figure 1B), additional affected and unaffected family
members were screened considering co-segregation.
Primers used for mutation validation and PCR conditions
are as following. A set of primers (Left Primer 5′-tgtaaaac-
gacggccagtGAGGCACTCTTGGTTCCATC-3′ and Right
Primer 5′-caggaaacagctatgaccGTGGATACGCACCCAT-
GAAC-3′) was chosen to amplify the region of the LDLR
gene encompassing the c.1359-1G >A variant (562 bp
length). Standard PCR was carried out in a 10 μl volume
containing 10 ng genomic DNA, 5 pmol of each primer
and 4 μl of Mastermix (VWR International GmbH,Darmstadt, Germany). Samples were processed in a
Sensoquest labcycler with a standard touchdown PCR
program (annealing temperature from 61°C-55°C).
Results and discussion
We analyzed an extended German MI-family consisting
of 53 members of whom 13 were affected with CAD and/
or MI (Figure 1A). Of these, 18 family members were
available for genetic analysis. Based on the phenotypic
presentation in this family, we suspected an autosomal
dominant mode of inheritance. Therefore, we decided to
carry out whole-exome sequencing of three affected family
members to unravel the genetic cause of CAD/MI in this
family.
The amount of disease-unspecific variants present in
the downstream analysis of whole-exome sequencing is
largely influenced by the subset of family members that
are selected for the initial analysis [18,19]. To optimize
the variant search, one strategy is to select distantly re-
lated family members. Whereas siblings share 50% of the
genetic variants, cousins share only 12.5% [20]. Hence,
we selected cousins instead of siblings to reduce the
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the chance for identifying the truly disease-causing vari-
ants (Figure 1A; III.3, III.18, and IV.7) [21,22].
To identify the causal variant in this family, we based
our filtering on three assumptions: (1) the variant is
inherited in an autosomal dominant mode of inherit-
ance; (2) the variant is very rare (<0.1%) in the general
population; and (3) most affected family members carry
the variant (high penetrance).
The sequencing was performed on a Genome Analyzer
llx system (Illumina) after in-solution enrichment of
exonic sequences. The exome sequencing revealed an
average read depth of 155 with minimum 84% of the
target regions covered at least 20X.
Whole-exome sequencing revealed around 39,000 vari-
ants in total and approximately 20,000 located in exonic re-
gions. We filtered the variants using the frequencies stated
in 1000 Genomes (1 kG, Annovar version 1000g2012apr),
Exome Sequencing Project (ESP, Annovar version 6500)
and in internal exome data (8 samples sequenced with
the same platform). Around 1,800 variants were found
with a frequency less than 0.1% in ESP and 1 kG. In a
next filtering step, we kept only variants that were con-
served and outside regions of segmental duplication,
leaving ~825 variants. To identify variants with poten-
tially severe function-altering effects, we filtered all variants
based on avsift score >0.05 and “HIGH” effect predicted
using Annovar and SnpEFF. These variants are either
amino acid changes, stop gain, stop loss or splice-site mu-
tations (more details can be found in Table 2). Only one
variant, a G > A substitution in the acceptor splice-site of
exon 10 in the LDLR gene (IVS9-1G >A or c.1359-1G >A),
was shared by the three sequenced family members and
was validated by Sanger-sequencing.
This G > A substitution results in the loss of a splice-site
with a predicted splice-site score of −4.2 for the variant
versus 6.8 for the reference allele [http://rulai.cshl.edu].
We genotyped this variant in all family members availableTable 2 Bioinformatic filtering of the family members
that were exome sequenced
Filter III.3 III.18 IV.7 Mean
Total aligned variants 38,702 38,408 38,775 38,628
Variants (exome) 20,344 20,387 20,173 20,301
Not in internal controls 1,995 2,123 2,097 2,072
Variants with frequency
<0.1% in 1000G and ESP
1,643 1,885 1,864 1,797
Conserved and no
segmental duplication
713 900 862 825
snpEFF =HIGH and AVSIFT <0.05 7 18 19 15
Shared variants 1
The data was annotated using annovar [16] (Version August 2013). Functional
prediction was performed with snpEFF [17] (build 2014-01-16) and
AVSIFT (Annovar).for genetic analysis to check for co-segregation with the
disease. There were 18 (one related by marriage) family
members available for genotyping. Of these, three were af-
fected and these carried the LDLR-variant. Of the 14
unaffected family members, which were not related by
marriage, three carried the variant. The three un-
affected mutation carriers were, at the time included in
this analysis, 48, 54 and 54 years old. Since MI is a
late-onset disease, we expect the disease to occur late
in life. Hence, the affection status regarding MI must
be considered unknown at this point.
Since the 1990s, it is well established that mutations in
the LDLR gene are the major cause for familial hyperchol-
esterolemia [1,23]. Around 90% of all known disease-
causing mutations (more than 1,800 mutations are listed
in HGMD (version 2013.4)) for FH are found in the LDLR
gene [3,24,25]. FH is also caused by mutations in the
APOB and PCSK9 genes, with frequencies of around 5%
and ~1% respectively [4,26].
We compared the LDL-C levels of the family members
that carry the variant with those that do not carry the vari-
ant. The results showed that the variant co-segregates
with increased LDL-C levels (LOD 4.3). The average LDL-
C levels were significantly increased in mutation carriers
compared with non-mutation carriers (279 mg/dL versus
155 mg/dL). However, the plasma levels were highly
variable ranging from 183 mg/dL to 354 mg/dL; this fact
misled the clinical diagnosis in the index patient (188,
corrected for statin use 279 mg/dL). To estimate the
functional implication of the identified variant, we sys-
tematically searched the literature. This revealed that
the LDLR variant has been previously described as
disease-causing in families with FH [27,28].
This variant is reported to originate from the south of
the Netherlands and to significantly increase the LDL-C
levels and hence cause a higher risk of premature CVD.
The risk increase was found to be 15.95% for mutation
carriers compared to unaffected relatives [29]. In our ana-
lyzed family, all but one mutation carrier have LDL-C
levels above 190 mg/dL. This result clearly underlines the
previous reported significant risk increase.
The variant cause an abnormally spliced transcript, which
results in a deletion of 7 bp and a frame shift with prema-
ture termination [30]. The deletion affects the normal
acceptor splice site in the 9th intron. This leads to a
cryptic splice site that consist of the 6th and 7th nucleo-
tide of exon 10.
The variant is likely to cause haploinsufficiency because
of the truncated transcript and hence nonsense-mediated
decay. However, even a protein product would lead to a
loss-of-function of the receptor since several important
domains of the receptor would be missing, such as the
crucial transmembrane region, the C-terminal part of the
epidermal growth factor precursor homology domain, the
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and the cytoplasmic domain. Other variants lacking these
domains have been reported to have reduced activity
(around 2%) and are classified as null allele (class 1) muta-
tions [31]. These mutations produce normal mRNA tran-
scripts, however, in reduced concentration [32], which
explains the increased risk of FH caused by this mutation.
With FH as the underlying cause of MI in this family,
we could have anticipated a mutation in the LDLR gene.
However, the index patient was referred to us and in-
cluded in our study with the diagnosis of premature MI/
CABG and positive family history for CAD.
The varying LDL-C levels in this family had initially
hindered the diagnosis of FH. It is, however, well known,
that the LDL-C levels may vary remarkably even among
individuals with the same mutation. One explanation for
this is that other modifying factors are present [31]. One
such mutation was described by Hobbs et al. [31]. They
reported a family in which one-third of the mutation
carriers have LDL concentrations below the 90th per-
centile. They suggested the existence of a dominant gene
that suppresses the effect of the LDL receptor mutation.
Hence, the fact that one of our mutation carriers have
LDL-C levels below 190 mg/dL might have similar explan-
ation and demonstrate the complexity of even expected
monogenic disease variants.
The result of this study underlines the power of whole-
exome sequencing approaches to identify disease-causing
variants. Whole-exome sequencing is a promising tool
to identify the cause of a disease in families with unclear
etiology of MI.
Conclusion
We strongly suggest that whole-exome sequencing can
be used for stratified medicine. If we know the disease-
causing variant in affected families, we can enable specific
preventive treatment of so-far unaffected mutation carriers
and this may prevent or delay the onset of the disease. In
addition, having overseen FH in the family at hand, we be-
lieve that the systematic sequencing of LDLR pathway
genes may accelerate the diagnostic work-up.
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